comprehensive -WSS

comprehensive

author：explore 2025-10-02 18:49:28 - browse：5

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： CDC says it’s too soon to assess risk posed by Covid subvariant

WSS

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Boston's new lab space is opening empty

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Wegovy improves function in certain heart failure patients

Medicare coverage of Wegovy, once blocked, now looks possible

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

23andMe had bad news about my health. I wish a person had delivered it

Boston's new lab space is opening empty

Sports medicine is finally prioritizing gender equality

Abortion policy in the spotlight at Republican debate

Jerome Adams on the need for new antivirals for Covid

Kellogg’s is going to war over Mexico’s nutrition label rules

Virginia high school admissions case could be legal follow

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Walensky prepares to leave CDC — and Congress — behind

Boston's new lab space is opening empty

Wikipedia

Boston's new lab space is opening empty

FDA advisory panel to debate high blood pressure devices

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

How the drug

Vivek Ramaswamy made waves in the debate, much as in biotech

knowledge

entertainment

Wikipedia

knowledge